Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and uric acid: More good news!

J Diabetes Complications. 2023 Jul;37(7):108510. doi: 10.1016/j.jdiacomp.2023.108510. Epub 2023 May 21.

¹ Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, Sindos, Greece; School of Medicine, European University Cyprus, Nicosia, Cyprus. Electronic address: nikikatsiki@hotmail.com.
² Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), School of Medicine, University of Palermo, Italy.
³ Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London Medical School, University College London (UCL), London, UK; Department of Clinical Biochemistry, Royal Free Hospital Campus, UCL, London, UK.

No abstract available

Keywords: Dapagliflozin; Empagliflozin; Gout; Heart failure; Sodium-glucose co-transporter-2 inhibitors; Uric acid.

Publication types